1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,150 | 6,450 | 18.07. | |
| 6,150 | 6,450 | 18.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | HSI Closes at 24,498, Down 18 pts; HSTI Closes at 5,448, Up 30 pts; BEIGENE Up over 10%; BEIGENE, SINO BIOPHARM, HANSOH PHARMA, JOHNSON ELEC H, KEYMED BIO-B Hit New Highs; Market Turnover Rises | 6 | AASTOCKS | ||
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | HSI Closes Midday at 24,534, Up 17 pts; HSTI Closes Midday at 5,434, Up 15 pts; BEIGENE Up over 8%; BEIGENE, HANSOH PHARMA, CHINAHONGQIAO, JOHNSON ELEC H, KEYMED BIO-B Hit New Highs | 8 | AASTOCKS | ||
| 26.06. | KEYMED BIO-B (02162): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025 | - | HKEx | ||
| 19.06. | KEYMED BIO-B (02162): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 19.06. | KEYMED BIO-B (02162): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE | - | HKEx | ||
| 13.06. | Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine | 616 | PR Newswire | CHENGDU, China, June 13, 2025 /PRNewswire/ -- On June 12, Keymed Biosciences Inc. (HKEX: 02162) announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases... ► Artikel lesen | |
| 11.06. | KEYMED BIO-B (02162): (1) PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE AND (2) SALE OF SHARES BY THE TOP-UP ... | 1 | HKEx | ||
| 28.04. | KEYMED BIO-B (02162): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.04. | KEYMED BIO-B (02162): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 28.04. | KEYMED BIO-B (02162): (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) ... | - | HKEx | ||
| 28.04. | KEYMED BIO-B (02162): 2024 ANNUAL REPORT | - | HKEx | ||
| 27.04. | Keymed Biosciences gibt die IND-Genehmigung für CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt | 81 | PR Newswire | CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder das "Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein... ► Artikel lesen | |
| 25.04. | Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors | 305 | PR Newswire | CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed... ► Artikel lesen | |
| 07.04. | Keymed Biosciences: Daten aus Phase-III-Studie zu Stapokibart gegen saisonale allergische Rhinitis in Nature Medicine veröffentlicht | 253 | PR Newswire | CHENGDU, China, 7. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder "Unternehmen") gab heute bekannt, dass die renommierte medizinische... ► Artikel lesen | |
| 05.04. | Keymed Biosciences: The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine | 664 | PR Newswire | CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published... ► Artikel lesen | |
| 26.03. | Keymed Biosciences Announces Annual Results of 2024 | 138 | PR Newswire | CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate... ► Artikel lesen | |
| 24.03. | KEYMED BIO-B (02162): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 24.03. | KEYMED BIO-B (02162): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 24.03. | KEYMED BIO-B (02162): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024; AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 12.03. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | 2 | HKEx |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| IMMUNOVANT | 17,910 | -2,02 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| EVOTEC | 7,456 | +0,59 % | Biotech-Übernahmekarussell nimmt Fahrt auf! BioNTech, Evotec, Merck & Co., BioNxt Solutions Aktie! | Das Übernahmekarussell dreht sich im Biotech-Sektor wieder schneller. Jüngstes Beispiel ist die Übernahme von Verona Pharma durch Merck. Der US-Konzern lässt sich dies 3 Mrd. USD kosten. Deutlich günstiger... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,845 | +5,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| SUMMIT THERAPEUTICS | 26,200 | -5,18 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| BIONTECH | 94,40 | -2,13 % | BioNTech zwischen Forschung und Flaute - Was Anleger jetzt wissen müssen!! | ||
| AVIDITY BIOSCIENCES | 33,740 | -0,88 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| ARVINAS | 7,350 | -5,34 % | Arvinas Inc.: Arvinas Announces Retirement of Chief Executive Officer and Succession Plan | - John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor - - Dr. Houston to Remain Chairperson of Arvinas Board of Directors... ► Artikel lesen | |
| VERVE THERAPEUTICS | 10,915 | -0,32 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly | ||
| TELOMIR PHARMACEUTICALS | 2,300 | +90,08 % | Telomir Pharmaceuticals, Inc: Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin | New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,730 | -4,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 12,080 | -0,29 % | Sarepta Therapeutics-Aktie +35%: Ist das die Wende? | Die Kursentwicklung der Sarepta Therapeutics -Aktie trieb Anlegern in jüngster Vergangenheit nur die Tränen in die Augen. In den letzten zwölf Monaten lösten sich fast -90% des Börsenwerts des Biotech-Unternehmens... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,500 | +2,29 % | Cogent Biosciences auf Rekordhoch: Positive Studienergebnisse und Kapitalerhöhung beflügeln Kurs | ||
| CRISPR THERAPEUTICS | 56,00 | 0,00 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Aktie kommt in Fahrt - jetzt noch kaufen? | Die Aktie des AKTIONÄR-Depotwerts CRISPR Therapeutics hat sich in den vergangenen Wochen enorm stark entwickelt. Zuletzt hat sich die Aufwärtsbewegung sogar noch einmal beschleunigt. Seit dem Tief Anfang... ► Artikel lesen |
Das Unternehmen KEYMED BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.